Leishmaniasis, a protozoal infection, is a growing health concern with 1.5 million new cases reported annually resulting in a wide spectrum of disease and clinical presentations. The disease is endemic in 98 countries with increasing prevalence in non-endemic areas. There are various treatment approaches that are often individualized based on host and parasite factors. Current treatment guidelines and data are variable and provide limited direction for specific treatment plans. Additionally, current recommended therapies are not benign, and are expensive and unavailable to most patients, especially in low-resource areas where leishmaniasis is most prevalent. Here, we report the diagnosis and successful treatment of cutaneous leishmaniasis in a 65-year-old male, who recently traveled to Mexico. Initial treatment with topical antifungals and oral antibiotics was ineffective. After successive treatment with local liquid nitrogen, the lesions completely resolved with no adverse effects or recurrence. Given there is limited evidence-based data supporting cryotherapy treatment as a first-line treatment, this report supports the efficacy of cryotherapy as a safe, cost-effective, and accessible treatment for cutaneous leishmaniasis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348073 | PMC |
http://dx.doi.org/10.7759/cureus.41871 | DOI Listing |
Indian Dermatol Online J
December 2024
Department of Clinical Research, CUTIS Academy of Cutaneous Sciences, Bengaluru, Karnataka, India.
Background: Laser therapy has emerged as an innovative approach for managing various nail conditions, offering precise targeting, minimal invasiveness, and favorable safety profiles. This review analyzes the literature on laser therapy for nail indications, encompassing onychomycosis, nail psoriasis, nail warts, ingrown toenails, onychodystrophy, nail pigmentation disorders, and nail tumors.
Methods: PubMed and Google Scholar databases were searched to identify articles on laser therapy using specific key terms related to nail conditions (e.
Indian Dermatol Online J
December 2024
Department of Dermatology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
Introduction: Nail psoriasis is a relatively unexplored clinical feature in the Indian population. Its correlation with cutaneous, musculoskeletal, and serological manifestations was analyzed.
Material And Methods: This study included 45 patients with clinically evident nail psoriasis.
J Oncol Pharm Pract
January 2025
Department of Oncology, Evaggelismos General Hospital, Athens, Greece.
Introduction: Pembrolizumab is an immune checkpoint inhibitor widely administered for the treatment of various malignancies. Despite its effectiveness, its distinctive mechanism of action may lead to immune-related adverse events, most frequently affecting cutaneous tissues. Hair-related adverse events, although uncommon, include conditions such as alopecia areata and alterations in hair texture or type.
View Article and Find Full Text PDFBMC Pharmacol Toxicol
January 2025
Department of Basic Sciences, Faculty of Allied Health Science, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
Background: Dermatophytes, the primary causative agents of superficial cutaneous fungal infections in humans, present a significant therapeutic challenge owing to the increasing prevalence of recurrent infections and the emergence of antifungal resistance. To address this critical gap, this study was designed to investigate the antifungal potential of 3-benzylideneindolin-2-one against dermatophytes and assess its in vivo toxicological profile using brine shrimp and zebrafish embryo models.
Methods: The antifungal activity of 3-benzylideneindolin-2-one was evaluated against 30 clinical isolates of dermatophyte species, including Trichophyton mentagrophytes, Trichophyton rubrum, Microsporum gypseum, Microsporum canis, and Epidermophyton floccosum, by determining the minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) using the broth microdilution method.
J Immunother Cancer
January 2025
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
Background: ATOR-1017 (evunzekibart) is a human agonistic immunoglobulin G4 antibody targeting the costimulatory receptor 4-1BB (CD137). ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cell death.
Methods: In this first-in-human, multicenter, phase I study, ATOR-1017 was administered intravenously every 21 days as a monotherapy to patients with advanced, unresectable solid tumors having received multiple standard-of-care treatments.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!